<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00204295</url>
  </required_header>
  <id_info>
    <org_study_id>FET-HT-MS</org_study_id>
    <nct_id>NCT00204295</nct_id>
  </id_info>
  <brief_title>Study on Amino Acid Uptake in Brain Tumors</brief_title>
  <official_title>Phase 2 Study on Brain Tumor Uptake of the Amino Acid O-(2-[F-18]Fluorethyl)-L-Tyrosin (FET)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Muenster</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Muenster</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the uptake of the amino acid&#xD;
      O-(2-[F-18]Fluorethyl)-L-tyrosin (FET) in human brain tumors using positron emission&#xD;
      tomography. A comparison to MRI and histopathological samples is used.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Radioactively labelled amino acids have been used for years to delineate primary brain tumors&#xD;
      and for the early detection of tumor recurrence. Positron emission tomography studies&#xD;
      indicate that the extent of amino acid uptake correlates to the true histological extent of&#xD;
      gliomas. Recently a fluorine-18 labelled amino acid has been introduced&#xD;
      (O-(2-[F-18]Fluorethyl)-L-tyrosin (FET)), which is suitable for routine use in brain tumor&#xD;
      patients. There is evidence that this amino acid is transported into brain and brain tumors&#xD;
      by the amino acid transport of the L-type. The cDNA of this L-transporter has recently been&#xD;
      cloned and has been shown to be identical to the light chain of the 4F2-antigen (CD98), which&#xD;
      has previously been described as marker of cell growth and proliferation.&#xD;
&#xD;
      The heavy chain of this heterodimer is known to modulate integrins which are thought to play&#xD;
      a fundamental role in glioma invasion.&#xD;
&#xD;
      Besides the evaluation of the diagnostic capability of FET in brain tumors, a comparison of&#xD;
      FET uptake in vivo and CD98 expression ex-vivo is performed with tissue slices as available&#xD;
      after routine surgery in glioma patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>January 2004</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Histological samples where available</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>CD98 staining where available</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical follow-up for at least one year</measure>
  </secondary_outcome>
  <enrollment>60</enrollment>
  <condition>Brain Neoplasms</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>O-(2-[F-18]Fluorethyl)-L-Tyrosin (FET) - PET</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with suspected primary brain tumors&#xD;
&#xD;
          -  CT or MRI showing lesion of &gt;= 2,5 cm&#xD;
&#xD;
          -  Any age; parents informed consent in children available&#xD;
&#xD;
          -  Karnofsky-Index &gt;= 20 %&#xD;
&#xD;
          -  Referral by Depts. of Neurology, Neuro-Oncology, Neurosurgery, or Pediatric Neurology&#xD;
             at the UKM&#xD;
&#xD;
          -  Biopsy and/or surgery planned&#xD;
&#xD;
          -  Patient is able to lie during the PET scan for 50 minutes without moving โข Patient&#xD;
             must be able to give informed consent; signature must be present before the PET scan&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy or breast feeing&#xD;
&#xD;
          -  Patients, who by psychiatric disease are not able to give informed consent&#xD;
&#xD;
          -  Complete renal failure&#xD;
&#xD;
          -  Inclusion to other studies according to ยง 23 of the German radiation protection law&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthias Weckesser, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Nuclear Medicine, University Hospital Muenster</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Nuclear Medicine, University Hospital Muenster</name>
      <address>
        <city>Muenster</city>
        <state>NRW</state>
        <zip>D-48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2006</verification_date>
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>September 13, 2006</last_update_submitted>
  <last_update_submitted_qc>September 13, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 14, 2006</last_update_posted>
  <keyword>Brain neoplasms</keyword>
  <keyword>Positron-Emission Tomography</keyword>
  <keyword>Amino Acids</keyword>
  <keyword>Magnetic Resonance Imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

